These inhibitors are based on hydrazone derivatives produced using a novel synthetic route. The compounds react with the active site of nucleophilic enzyme, which typically have a nucleophile such as an amine, alcohol, or thiol on the side chain (for example - lysine, serine, and cysteine). In reacting at this site, the enzyme is inhibited. Such inhibition has potential therapeutic and investigational uses for many pathophysiological processes. Initial data demonstrates affinity to proteins implicated in various cancers.